Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Kidney repair? experimental cell therapy targets diabetic kidney decline

NCT ID NCT05018416

First seen Mar 15, 2026 · Last updated Apr 29, 2026 · Updated 10 times

Summary

This study tested an experimental cell therapy called REACT (rilparencel) in 53 adults with type 1 or type 2 diabetes and chronic kidney disease. The goal was to see if injecting a person's own kidney cells back into their kidneys could slow the loss of kidney function. The treatment is not a cure, but aims to help control the disease and delay the need for dialysis or transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Boise Kidney and Hypertension Institute - Frenova

    Nampa, Idaho, 83687, United States

  • Kidney Associates of Colorado, P.C. - Frenova

    Denver, Colorado, 80210-5073, United States

  • Nephrology Associates

    Newark, Delaware, 19713, United States

  • Nephrology and Hypertension Associates Ltd - Frenova

    Tupelo, Mississippi, 38801-6560, United States

  • Paragon Health, PC d/b/a Nephrology Center, PC - Frenova

    Kalamazoo, Michigan, 49007-3889, United States

Conditions

Explore the condition pages connected to this study.